Repurposed medications may guide future strategies for COVID-19 treatment.
Griffith’s Institute for Glycomics have made a promising discovery in the treatment and prevention of human parainfluenza virus.
Calls for new national clinical guidelines to improve the care of hundreds of thousands of Australians with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and potentially thousands more with Long Covid.
A drug normally used to prevent tissue rejection following organ transplants could be repurposed to help treat human metapneumovirus (HMPV) infection in children.
Low-dose Naltrexone may reduce Myalgic Encephalomyelitis/Chronic Fatigue Syndrome symptoms study finds.
Griffith University’s Institute for Glycomics celebrates the promotion of six of its researchers, in recognition of their outstanding contributions to...
Australian and German researchers from the international consortium iCAIR® (Fraunhofer International Consortium for Anti-Infective Research), comprising of Griffith University’s Institute...
